+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Hepatorenal Syndrome Treatment Market by Type (Type 1 Hepatorenal Syndrome, Type 2 Hepatorenal Syndrome), Treatment (Surgical Treatment, Therapeutics), End-User - Cumulative Impact of High Inflation - Forecast 2023-2030- Product Image
Global Hepatorenal Syndrome Treatment Market by Type (Type 1 Hepatorenal Syndrome, Type 2 Hepatorenal Syndrome), Treatment (Surgical Treatment, Therapeutics), End-User - Cumulative Impact of High Inflation - Forecast 2023-2030- Product Image
Sale

Global Hepatorenal Syndrome Treatment Market by Type (Type 1 Hepatorenal Syndrome, Type 2 Hepatorenal Syndrome), Treatment (Surgical Treatment, Therapeutics), End-User - Cumulative Impact of High Inflation - Forecast 2023-2030

  • PDF Icon

    Report

  • 243 Pages
  • May 2023
  • Region: Global
  • 360iResearch™
  • ID: 5336349
UP TO OFF until Jun 30th 2023
Description Jump to:
The Global Hepatorenal Syndrome Treatment Market size was estimated at USD 5,565.42 million in 2022, USD 6,279.07 million in 2023, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 12.95% to reach USD 14,753.17 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Hepatorenal Syndrome Treatment Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Hepatorenal Syndrome Treatment Market in order to forecast the revenues and analyze trends in each of following sub-markets:
  • Based on Type, market is studied across Type 1 Hepatorenal Syndrome and Type 2 Hepatorenal Syndrome. The Type 1 Hepatorenal Syndrome is projected to witness significant market share during forecast period.
  • Based on Treatment, market is studied across Surgical Treatment and Therapeutics. The Surgical Treatment is projected to witness significant market share during forecast period.
  • Based on End-User, market is studied across Academic & Research Institutes, Ambulatory Surgical Centers, and Hospitals & Clinics. The Ambulatory Surgical Centers is projected to witness significant market share during forecast period.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Hepatorenal Syndrome Treatment Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Hepatorenal Syndrome Treatment Market, including Aetna Inc., Baxter International Inc, Becton, Dickinson and Company, BioVie Inc, Cadila Healthcare Limited, Cumberland Pharmaceuticals Inc, Edwards Lifesciences Corporation, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Mallinckrodt Inc, Medtronic plc, Neovii Pharmaceuticals AG, Novartis International AG, Orphan Therapeutics, LLC, and PharmaIN Corporation.

The report provides insights on the following pointers:

  1. Market Penetration: Provides comprehensive information on the market offered by the key players
  2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
  3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
  5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  1. What is the market size and forecast of the Global Hepatorenal Syndrome Treatment Market?
  2. What are the inhibiting factors and impact of COVID-19 shaping the Global Hepatorenal Syndrome Treatment Market during the forecast period?
  3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Hepatorenal Syndrome Treatment Market?
  4. What is the competitive strategic window for opportunities in the Global Hepatorenal Syndrome Treatment Market?
  5. What are the technology trends and regulatory frameworks in the Global Hepatorenal Syndrome Treatment Market?
  6. What is the market share of the leading vendors in the Global Hepatorenal Syndrome Treatment Market?
  7. What modes and strategic moves are considered suitable for entering the Global Hepatorenal Syndrome Treatment Market?
Frequently Asked Questions about the Global Hepatorenal Syndrome Treatment Market

What is the estimated value of the Global Hepatorenal Syndrome Treatment Market?

The Global Hepatorenal Syndrome Treatment Market was estimated to be valued at $5565.42 Million in 2022.

What is the growth rate of the Global Hepatorenal Syndrome Treatment Market?

The growth rate of the Global Hepatorenal Syndrome Treatment Market is 12.9%, with an estimated value of $14753.17 Million by 2030.

What is the forecasted size of the Global Hepatorenal Syndrome Treatment Market?

The Global Hepatorenal Syndrome Treatment Market is estimated to be worth $14753.17 Million by 2030.

Who are the key companies in the Global Hepatorenal Syndrome Treatment Market?

Key companies in the Global Hepatorenal Syndrome Treatment Market include Aetna Inc., Baxter International Inc, Becton, Dickinson and Company, BioVie Inc, Cadila Healthcare Limited, Cumberland Pharmaceuticals Inc, Edwards Lifesciences Corporation, F. Hoffmann, La Roche AG and GlaxoSmithKline plc.
Report AttributeDetails
No. of Pages243
PublishedMay 2023
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 5565.42 Million
Forecasted Market Value ( USD ) by 2030 $ 14753.17 Million
Compound Annual Growth Rate12.9%
Regions CoveredGlobal
No. of Companies Mentioned15

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Hepatorenal Syndrome Treatment Market, by Type, 2022 vs 2030
4.3. Hepatorenal Syndrome Treatment Market, by Treatment, 2022 vs 2030
4.4. Hepatorenal Syndrome Treatment Market, by End-User, 2022 vs 2030
4.5. Hepatorenal Syndrome Treatment Market, by Region, 2022 vs 2030
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of severe liver damage which often leads to hepatorenal syndrome
5.1.1.2. Increasing fast track and orphan drug designations
5.1.1.3. Growing disease awareness & patient support programs
5.1.2. Restraints
5.1.2.1. Stringent government regulation and standards for approval
5.1.3. Opportunities
5.1.3.1. Increasing research & development to incorporate advanced technologies
5.1.3.2. Rising cases of liver damage and cirrhosis
5.1.4. Challenges
5.1.4.1. Side-effects and risks related to drug usage
5.2. Market Trends
5.3. Cumulative Impact of COVID-19
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter’s Five Forces Analysis
5.6.1. Threat of New Entrants
5.6.2. Threat of Substitutes
5.6.3. Bargaining Power of Customers
5.6.4. Bargaining Power of Suppliers
5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework
5.9. Client Customization
6. Hepatorenal Syndrome Treatment Market, by Type
6.1. Introduction
6.2. Type 1 Hepatorenal Syndrome
6.3. Type 2 Hepatorenal Syndrome
7. Hepatorenal Syndrome Treatment Market, by Treatment
7.1. Introduction
7.2. Surgical Treatment
7.3. Therapeutics
8. Hepatorenal Syndrome Treatment Market, by End-User
8.1. Introduction
8.2. Academic & Research Institutes
8.3. Ambulatory Surgical Centers
8.4. Hospitals & Clinics
9. Americas Hepatorenal Syndrome Treatment Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Hepatorenal Syndrome Treatment Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Hepatorenal Syndrome Treatment Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
13. Company Usability Profiles
13.1. Aetna Inc.
13.2. Baxter International Inc
13.3. Becton, Dickinson and Company
13.4. BioVie Inc
13.5. Cadila Healthcare Limited
13.6. Cumberland Pharmaceuticals Inc
13.7. Edwards Lifesciences Corporation
13.8. F. Hoffmann-La Roche AG
13.9. GlaxoSmithKline plc
13.10. Mallinckrodt Inc
13.11. Medtronic plc
13.12. Neovii Pharmaceuticals AG
13.13. Novartis International AG
13.14. Orphan Therapeutics, LLC
13.15. PharmaIN Corporation
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. HEPATORENAL SYNDROME TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2022 VS 2030
FIGURE 3. HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
FIGURE 5. HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2022 VS 2030 (%)
FIGURE 6. HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2022 VS 2030 (%)
FIGURE 7. HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 8. HEPATORENAL SYNDROME TREATMENT MARKET DYNAMICS
FIGURE 9. HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 10. HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 14. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 15. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 16. HEPATORENAL SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2022
FIGURE 17. HEPATORENAL SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2022
List of Tables
TABLE 1. HEPATORENAL SYNDROME TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 5. HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE 1 HEPATORENAL SYNDROME, BY REGION, 2018-2030 (USD MILLION)
TABLE 6. HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE 2 HEPATORENAL SYNDROME, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 8. HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 11. HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 15. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 16. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 17. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 18. ARGENTINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 19. ARGENTINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 20. ARGENTINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 21. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 22. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 23. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 24. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 25. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 26. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 27. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 28. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 29. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 30. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 31. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 32. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 33. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 34. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 35. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 36. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 37. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 38. AUSTRALIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 39. AUSTRALIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 40. AUSTRALIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 41. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 42. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 43. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 44. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 45. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 46. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 47. INDONESIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 48. INDONESIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 49. INDONESIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 50. JAPAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 51. JAPAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 52. JAPAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 53. MALAYSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 54. MALAYSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 55. MALAYSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 56. PHILIPPINES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 57. PHILIPPINES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 58. PHILIPPINES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 59. SINGAPORE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 60. SINGAPORE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 61. SINGAPORE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 62. SOUTH KOREA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 63. SOUTH KOREA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 64. SOUTH KOREA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 65. TAIWAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 66. TAIWAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 67. TAIWAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 68. THAILAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 69. THAILAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 70. THAILAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 71. VIETNAM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 72. VIETNAM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 73. VIETNAM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 74. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 75. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 78. DENMARK HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 79. DENMARK HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 80. DENMARK HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 81. EGYPT HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 82. EGYPT HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 83. EGYPT HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 84. FINLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 85. FINLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 86. FINLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 87. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 88. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 89. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 90. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 91. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 92. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 93. ISRAEL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 94. ISRAEL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 95. ISRAEL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 96. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 97. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 98. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 99. NETHERLANDS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 100. NETHERLANDS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 101. NETHERLANDS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 102. NIGERIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 103. NIGERIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 104. NIGERIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 105. NORWAY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 106. NORWAY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 107. NORWAY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 108. POLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 109. POLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 110. POLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 111. QATAR HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 112. QATAR HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 113. QATAR HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 114. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 115. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 116. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 117. SAUDI ARABIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 118. SAUDI ARABIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 119. SAUDI ARABIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 120. SOUTH AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 121. SOUTH AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 122. SOUTH AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 123. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 124. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 125. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 126. SWEDEN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 127. SWEDEN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 128. SWEDEN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 129. SWITZERLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 130. SWITZERLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 131. SWITZERLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 132. TURKEY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 133. TURKEY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 134. TURKEY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 135. UNITED ARAB EMIRATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 136. UNITED ARAB EMIRATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 137. UNITED ARAB EMIRATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 138. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 139. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 140. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 141. HEPATORENAL SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, SCORES, 2022
TABLE 142. HEPATORENAL SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, BUSINESS STRATEGY, 2022
TABLE 143. HEPATORENAL SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, PRODUCT SATISFACTION, 2022
TABLE 144. HEPATORENAL SYNDROME TREATMENT MARKET RANKING, BY KEY PLAYER, 2022
TABLE 145. HEPATORENAL SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2022
TABLE 146. HEPATORENAL SYNDROME TREATMENT MARKET LICENSE & PRICING

Companies Mentioned

  • Aetna Inc.
  • Baxter International Inc
  • Becton, Dickinson and Company
  • BioVie Inc
  • Cadila Healthcare Limited
  • Cumberland Pharmaceuticals Inc
  • Edwards Lifesciences Corporation
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Mallinckrodt Inc
  • Medtronic plc
  • Neovii Pharmaceuticals AG
  • Novartis International AG
  • Orphan Therapeutics, LLC
  • PharmaIN Corporation

Methodology

Loading
LOADING...

Related Topics

Related Reports

Global Acute Kidney Injury Treatment Market by Type, Treatment, End-User - Cumulative Impact of High Inflation - Forecast 2023-2030 - Product Image

Global Acute Kidney Injury Treatment Market by Type, Treatment, End-User - Cumulative Impact of High Inflation - Forecast 2023-2030

  • Report
  • 252 Pages
  • Global
From
Hepatorenal Syndrome Treatment Market Research Report by Type (Type 1 Hepatorenal Syndrome, Type 2 Hepatorenal Syndrome), Treatment (Surgical Treatment, Therapeutics), End-User - United States Forecast 2023-2030 - Product Image

Hepatorenal Syndrome Treatment Market Research Report by Type (Type 1 Hepatorenal Syndrome, Type 2 Hepatorenal Syndrome), Treatment (Surgical Treatment, Therapeutics), End-User - United States Forecast 2023-2030

  • Report
  • 125 Pages
  • United States
From
Nephrology. A Comprehensive Guide to Renal Medicine. Edition No. 1. Lecture Notes - Product Image

Nephrology. A Comprehensive Guide to Renal Medicine. Edition No. 1. Lecture Notes

  • Book
  • 342 Pages
Sleisenger and Fordtran's Gastrointestinal and Liver Disease Review and Assessment. Edition No. 11 - Product Image

Sleisenger and Fordtran's Gastrointestinal and Liver Disease Review and Assessment. Edition No. 11

  • Book
Sleisenger and Fordtran's Gastrointestinal and Liver Disease- 2 Volume Set. Pathophysiology, Diagnosis, Management. Edition No. 11 - Product Image

Sleisenger and Fordtran's Gastrointestinal and Liver Disease- 2 Volume Set. Pathophysiology, Diagnosis, Management. Edition No. 11

  • Book
Copyright © 2002-2023 Research and Markets. All Rights Reserved.